BACKGROUND: Pseudomonas aeruginosa (Pa) is the most important pathogen infecting the airways in individuals with cystic fibrosis. A key question is whether children with newly acquired Pa infection who are able to achieve sustained eradication after early antipseudomonal therapy demonstrate improved long-term health outcomes compared with those who are unable to achieve a sustained microbiologic response. METHODS: This cohort study utilized observational follow-up data on children participating in the Early Pseudomonas Infection Control trial who receivedstandardized therapy for newly acquired Pa. Sustained eradicators were defined as those who maintained Pa-negative cultures for 12 months after initial antipseudomonal therapy. Associations between eradication status and outcomes were assessed. RESULTS: Of the 249 trial participants included in the study, 172 (69%) achieved sustained eradication of Pa during the trial (sustained eradicators). Over the median 5-year follow-up, sustained eradicators had a 74% reduced risk of developing chronic Pa (hazard ratio [HR], 0.26; 95% confidence interval [CI], .17-.40) and a 57% reduced risk of mucoidy (HR, 0.43; 95% CI, .25-.73) compared with nonsustained eradicators. Sustained eradicators had significantly less anti-Pa antibiotic usage during follow-up compared with nonsustained eradicators. There was no association between eradication status and clinical outcomes including rate of exacerbation and lung function decline. CONCLUSIONS: This is the first study to quantify the long-term durability of microbiological response associated with early antipseudomonal therapy, demonstrating the critical importance of optimizing antipseudomonal therapies during early Pa infection. The clinical impact of failure to achieve sustained Pa eradication remains unclear, however, and may be confounded by anti-Pa antibiotic usage. CLINICAL TRIALS REGISTRATION: NCT00097773.
RCT Entities:
BACKGROUND:Pseudomonas aeruginosa (Pa) is the most important pathogen infecting the airways in individuals with cystic fibrosis. A key question is whether children with newly acquired Pa infection who are able to achieve sustained eradication after early antipseudomonal therapy demonstrate improved long-term health outcomes compared with those who are unable to achieve a sustained microbiologic response. METHODS: This cohort study utilized observational follow-up data on children participating in the Early Pseudomonas Infection Control trial who received standardized therapy for newly acquired Pa. Sustained eradicators were defined as those who maintained Pa-negative cultures for 12 months after initial antipseudomonal therapy. Associations between eradication status and outcomes were assessed. RESULTS: Of the 249 trial participants included in the study, 172 (69%) achieved sustained eradication of Pa during the trial (sustained eradicators). Over the median 5-year follow-up, sustained eradicators had a 74% reduced risk of developing chronic Pa (hazard ratio [HR], 0.26; 95% confidence interval [CI], .17-.40) and a 57% reduced risk of mucoidy (HR, 0.43; 95% CI, .25-.73) compared with nonsustained eradicators. Sustained eradicators had significantly less anti-Pa antibiotic usage during follow-up compared with nonsustained eradicators. There was no association between eradication status and clinical outcomes including rate of exacerbation and lung function decline. CONCLUSIONS: This is the first study to quantify the long-term durability of microbiological response associated with early antipseudomonal therapy, demonstrating the critical importance of optimizing antipseudomonal therapies during early Pa infection. The clinical impact of failure to achieve sustained Pa eradication remains unclear, however, and may be confounded by anti-Pa antibiotic usage. CLINICAL TRIALS REGISTRATION: NCT00097773.
Authors: Cori Daines; Donald VanDeVanter; Umer Khan; Julia Emerson; Sonya Heltshe; Sharon McNamara; Michael Anstead; Markus Langkamp; Gerd Doring; Felix Ratjen; Bonnie Ramsey; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld Journal: J Cyst Fibros Date: 2014-07-11 Impact factor: 5.482
Authors: Lisa Saiman; Michael Anstead; Nicole Mayer-Hamblett; Larry C Lands; Margaret Kloster; Jasna Hocevar-Trnka; Christopher H Goss; Lynn M Rose; Jane L Burns; Bruce C Marshall; Felix Ratjen Journal: JAMA Date: 2010-05-05 Impact factor: 56.272
Authors: Miriam M Treggiari; George Retsch-Bogart; Nicole Mayer-Hamblett; Umer Khan; Michal Kulich; Richard Kronmal; Judy Williams; Peter Hiatt; Ronald L Gibson; Terry Spencer; David Orenstein; Barbara A Chatfield; Deborah K Froh; Jane L Burns; Margaret Rosenfeld; Bonnie W Ramsey Journal: Arch Pediatr Adolesc Med Date: 2011-09
Authors: Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman Journal: Am J Respir Crit Care Med Date: 2014-08-01 Impact factor: 21.405
Authors: Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey Journal: J Cyst Fibros Date: 2012-09-01 Impact factor: 5.482
Authors: Edith T Zemanick; Julia Emerson; Valeria Thompson; Sharon McNamara; Wayne Morgan; Ronald L Gibson; Margaret Rosenfeld Journal: Pediatr Pulmonol Date: 2014-03-18
Authors: Matthew R Crull; Ranjani Somayaji; Kathleen J Ramos; Ellen Caldwell; Nicole Mayer-Hamblett; Moira L Aitken; David P Nichols; Ali Rowhani-Rahbar; Christopher H Goss Journal: Clin Infect Dis Date: 2018-09-14 Impact factor: 9.079
Authors: S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld Journal: J Cyst Fibros Date: 2017-10-28 Impact factor: 5.482
Authors: Sarwat Chowdhury; Kelly N Owens; R Jason Herr; Qin Jiang; Xinchao Chen; Graham Johnson; Vincent E Groppi; David W Raible; Edwin W Rubel; Julian A Simon Journal: J Med Chem Date: 2017-10-27 Impact factor: 7.446
Authors: P Vidya; L Smith; T Beaudoin; Y C Yau; S Clark; B Coburn; D S Guttman; D M Hwang; V Waters Journal: Eur J Clin Microbiol Infect Dis Date: 2016-01 Impact factor: 3.267
Authors: Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948